Answers are grounded in this paper and cite their sources.
situation on the basis of the number of anginal attacks and the effort required to produce them.It should always be stopped before the patient returns to work.Because of the danger of masking myocardial ischaemia, the numerous side-effects, and the risk of serious liver damage, iproniazid is not indicated for the patient with mild angina.Although the drug could theoretically give rise to "silent infarction," this did not happen in any of our patients.Two of them had infarcts while receiving iproniazid.Both were at rest at the time and had typical pain.The side-effects of iproniazid are described by Robitzek and Selikoff (1952) as, firstly, those referable to autonomic stimulation, including dryness of the mouth, constipation, delayed micturition, and difficulties in visuLal accommoda- tion ; secondly, those referable to central nervous system stimulation, including vertigo, muscle-twitching, hyper- reflexia, excitement, euphoria, somnolence; and, thirdly, those referable to antagonism to vitamin B, including peripheral neuropathy.Unfortunately these and other sideeffects limit the usefulness of the drug.Summary Iproniazid has been given to 40 patients with severe angina pectoris from occlusive coronary atherosclerosis, and was highly effective in reducing the frequency and severity of anginal attacks.It appears to act by blocking pain and not by improving the coronary circulation.Side-effects are common ; many of our patients com- plained of giddiness and two developed pulmonary oedema, presumably from fluid retention.The blocking of angina may encourage the patient to be more active and may precipitate infarction.Because of this and the side-effects, the drug is not indicated for patients with mild angina pectoris.In the patient with severe and intractable angina it is of great value, especially if anti- coagulant therapy can be given in addition.The patient can often be helped over a prolonged ischaemic episode, the drug being withdrawn when the condition improves.We are grateful to Dr. Margaret Briggs, of Roche Products Limited, for her help and for supplies of marsilid.
No takes yet. Share an insight, caveat, or question.
Benaïm et al. (1958) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: